Cyclo-oxygenase (Cox)-2 is not upregulated in idiopathic pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001
Cell-specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 76s Year: 2001
PKCalpha deficiency in mice is associated with pulmonary vascular hyperresponsiveness to thromboxane A2 via increased TXA2 receptor expression Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Polymorphism of prostacyclin synthase gene in pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 5s Year: 2002
Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014
Upregulation of endothelial nitric oxide synthase in pulmonary artery of infants with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 694s Year: 2004
Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Roles of TIMP-1 in the development of the pulmonary involvement in sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 551s Year: 2004
Role of lysyl oxidases in pathogenesis of pulmonary emphysema Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia Year: 2017
Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
Chemokine mRNA expression profiling in pulmonary sarcoidosis Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008
Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Nonselective cyclo-oxygenase inhibition: effects on exhaled eicosanoids in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 424s Year: 2001
Regulation of WISP1 by profibrotic cytokines in pulmonary fibrosis Source: International Congress 2014 – Pulmonary fibrosis: receptors, signalling pathways and mesenchymal cells Year: 2014
SRC family kinase inhibition reduces NOX4 expression in bronchial epithelial cells from Idiopathic Pulmonary Fibrosis patients Source: International Congress 2019 – Damage and remodelling in pulmonary fibrosis Year: 2019
Inhibition of the miRNA familiy miR-130 restores the expression of CDKN1A (p21) and ameliorates hypoxia-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014
IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014